Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certepetide - Lisata Therapeutics

Next Previous
X
Search
Drug Profile

Certepetide - Lisata Therapeutics

Alternative Names: CEND-1; Internalised-arginylglycylaspartic Acid Cyclic Peptide; iRGD; LSTA-1; QLC-12102

Latest Information Update: 20 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DrugCendR
  • Developer Australasian Gastro-Intestinal Trials Group; Lisata Therapeutics; National Health and Medical Research Council Clinical Trials Centre; Qilu Pharmaceutical; The University of Kansas Cancer Center; University of Sydney
  • Class Antineoplastics; Cyclic peptides; Peptides
  • Mechanism of Action Integrin alphaV antagonists; Neuropilin-1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Glioma; Cholangiocarcinoma; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Glioblastoma; Pancreatic cancer; Solid tumours
  • Phase I/II Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 10 Dec 2024 Lisata Therapeutics completes enrolment in its phase Ib/IIa CENDIFOX trial for Pancreatic cancer, Colon cancer and Gastrointestinal cancer in USA (IV)
  • 12 Nov 2024 Lisata Therapeutics plans a phase Ib/IIa FORTIFIDE trial for Adenocarcinoma (Second-line or greater, Adjunctive therapy, Metastatic disease) first quarter of 2025 (IV) (NCT06592664)
  • 06 Nov 2024 Lisata Therapeutics and Valo Therapeutics enters into a preclinical research collaboration to evaluate Certepetide with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models for Melanoma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top